{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:41:48Z","timestamp":1762101708533},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s12325-015-0208-2","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T11:51:21Z","timestamp":1431345081000},"page":"391-403","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)"],"prefix":"10.1007","volume":"32","author":[{"given":"Javier","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Merker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"208_CR1","unstructured":"IDF Diabetes Atlas 6th Edition, 2013. Available from: http:\/\/www.idf.org\/sites\/default\/files\/EN_6E_Atlas_Full_0.pdf . Last accessed Nov, 2014."},{"key":"208_CR2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UKPDS Group","year":"1998","unstructured":"UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"208_CR3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"208_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, American Diabetes Association, European Association for Study of Diabetes, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193\u2013203.","journal-title":"Diabetes Care"},{"key":"208_CR5","unstructured":"National Institute for Health and Care Excellence. The management of type 2 diabetes: NICE clinical guideline 87. 2009. Available from: http:\/\/www.nice.org.uk\/guidance\/cg87 . Last accessed Aug, 2014."},{"key":"208_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","volume":"19","author":"AJ Garber","year":"2013","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, American Association of Clinical Endocrinologists, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327\u201336.","journal-title":"Endocr Pract."},{"key":"208_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1590\/S1020-49892007000600002","volume":"22","author":"G Lopez Stewart","year":"2007","unstructured":"Lopez Stewart G, Tambascia M, Rosas Guzm\u00e1n J, Etchegoyen F, Ortega Carri\u00f3n J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007;22:12\u201320.","journal-title":"Rev Panam Salud Publica."},{"key":"208_CR8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/03007995.2013.803053","volume":"29","author":"A Oguz","year":"2013","unstructured":"Oguz A, Benroubi M, Brismar K, et al. Clinical outcomes after 24\u00a0months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Curr Med Res Opin. 2013;29:911\u201320.","journal-title":"Curr Med Res Opin"},{"key":"208_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13300-012-0009-4","volume":"3","author":"A Liebl","year":"2012","unstructured":"Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther. 2012;3:9.","journal-title":"Diabetes Ther."},{"key":"208_CR10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"208_CR11","doi-asserted-by":"crossref","first-page":"C39","DOI":"10.2337\/diacare.21.3.C39","volume":"21","author":"R Klein","year":"1998","unstructured":"Klein R, Klein BEK. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care. 1998;21(Suppl 3):C39\u201343.","journal-title":"Diabetes Care"},{"key":"208_CR12","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc09-2260","volume":"33","author":"JB Buse","year":"2010","unstructured":"Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300\u20133.","journal-title":"Diabetes Care"},{"key":"208_CR13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.2040-1124.2012.00193.x","volume":"3","author":"Y Seino","year":"2012","unstructured":"Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves \u03b2-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:388\u201395.","journal-title":"J Diabetes Investig."},{"key":"208_CR14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\u00a0+\u00a0TZD). Diabetes Care. 2009;32:1224\u201330.","journal-title":"Diabetes Care"},{"key":"208_CR15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2014.5951","volume":"311","author":"A Wallia","year":"2014","unstructured":"Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315\u201325.","journal-title":"JAMA"},{"key":"208_CR16","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR, Thorne KI, Farmer AJ, 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716\u201330.","journal-title":"N Engl J Med."},{"key":"208_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3810\/pgm.2014.05.2757","volume":"126","author":"S Schwartz","year":"2014","unstructured":"Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med. 2014;126:66\u201384.","journal-title":"Postgrad Med"},{"key":"208_CR18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11096-012-9729-9","volume":"35","author":"S Russell","year":"2013","unstructured":"Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm. 2013;35:159\u201372.","journal-title":"Int J Clin Pharm."},{"key":"208_CR19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2265.2012.04483.x","volume":"77","author":"D Russell-Jones","year":"2012","unstructured":"Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf). 2012;77:489\u201399.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"208_CR20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258\u201366.","journal-title":"Diabetes Res Clin Pract"},{"key":"208_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39\u201347.","journal-title":"Lancet"},{"key":"208_CR22","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, ADOPT Study Group, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"key":"208_CR23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","volume":"81","author":"M Monami","year":"2008","unstructured":"Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"208_CR25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1463-1326.2011.01433.x","volume":"13","author":"AE Pontiroli","year":"2011","unstructured":"Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:1008\u201319.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"RE Ratner","year":"2013","unstructured":"Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4158\/EP13287.OR","volume":"20","author":"HW Rodbard","year":"2014","unstructured":"Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized BEGIN trials. Endocr Pract. 2014;20:285\u201392.","journal-title":"Endocr Pract."},{"key":"208_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2337\/diacare.23.1.45","volume":"23","author":"M Muggeo","year":"2000","unstructured":"Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23:45\u201350.","journal-title":"Diabetes Care"},{"key":"208_CR29","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","volume":"53","author":"T Heise","year":"2004","unstructured":"Heise T, Nosek L, R\u00f8nn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614\u201320.","journal-title":"Diabetes"},{"key":"208_CR30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"J Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5:435\u201346.","journal-title":"Diabetes Ther."},{"key":"208_CR31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/diacare.27.7.1535","volume":"27","author":"JB Brown","year":"2004","unstructured":"Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535\u201340.","journal-title":"Diabetes Care"},{"key":"208_CR32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","volume":"11","author":"L Blonde","year":"2009","unstructured":"Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets\u2014the TITRATE study. Diabetes Obes Metab. 2009;11:623\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR33","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080\u20136.","journal-title":"Diabetes Care"},{"key":"208_CR34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","volume":"51","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408\u201316.","journal-title":"Diabetologia"},{"key":"208_CR35","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/j.1464-5491.2012.03694.x","volume":"29","author":"BT Blak","year":"2012","unstructured":"Blak BT, Smith HT, Hards M, Maguire A, Gimeno V. A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabet Med. 2012;29:e191\u20138.","journal-title":"Diabet Med"},{"key":"208_CR36","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"208_CR37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, et al. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"208_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"key":"208_CR39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3111\/13696998.2011.610852","volume":"14","author":"C Fidler","year":"2011","unstructured":"Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646\u201355.","journal-title":"J Med Econ."},{"key":"208_CR40","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"key":"208_CR41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1742-1241.2009.02176.x","volume":"164","author":"T Kunt","year":"2009","unstructured":"Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;164:6\u201310.","journal-title":"Int J Clin Pract Suppl."},{"key":"208_CR42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/dme.12046","volume":"30","author":"JE Aikens","year":"2013","unstructured":"Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes. Diabet Med. 2013;30:338\u201344.","journal-title":"Diabet Med"},{"key":"208_CR43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ijcp.12388","volume":"68","author":"N Munro","year":"2014","unstructured":"Munro N, Barnett AH. Incidence, worry and discussion about dosing irregularities and self-treated hypoglycaemia amongst HCPs and patients with type 2 diabetes: results from the UK cohort of the Global Attitudes of Patient and Physicians (GAPP2) survey. Int J Clin Pract. 2014;68:692\u20139.","journal-title":"Int J Clin Pract"},{"key":"208_CR44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.curtheres.2013.06.004","volume":"75","author":"S Grandy","year":"2013","unstructured":"Grandy S, Fox KM, Hardy E, SHIELD Study Group. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Curr Ther Res Clin Exp. 2013;75:77\u201382.","journal-title":"Curr Ther Res Clin Exp."},{"key":"208_CR45","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1463-1326.2007.00804.x","volume":"9","author":"L Meneghini","year":"2007","unstructured":"Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes\u2014results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902\u201313.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR46","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1742-1241.2008.01742.x","volume":"62","author":"RP Hayes","year":"2008","unstructured":"Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008;62:860\u20138.","journal-title":"Int J Clin Pract"},{"key":"208_CR47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/dc09-1184","volume":"33","author":"AJ Karter","year":"2010","unstructured":"Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733\u20135.","journal-title":"Diabetes Care"},{"key":"208_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1463-1326.2012.01628.x","volume":"15","author":"JJ Holst","year":"2013","unstructured":"Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2013;15:3\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"9 Suppl 1","key":"208_CR49","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2013.06.011","volume":"126","author":"LF Meneghini","year":"2013","unstructured":"Meneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med. 2013;126(9 Suppl 1):S28\u201337.","journal-title":"Am J Med"},{"key":"208_CR50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","volume":"15","author":"R Balena","year":"2013","unstructured":"Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485\u2013502.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.diabet.2012.08.002","volume":"39","author":"J Vora","year":"2013","unstructured":"Vora J, Bain SC, Damci T, et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab. 2013;39:6\u201315.","journal-title":"Diabetes Metab."},{"key":"208_CR52","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","volume":"35","author":"JH DeVries","year":"2012","unstructured":"DeVries JH, Bain SC, Rodbard HW, Liraglutide-Detemir Study Group, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446\u201354.","journal-title":"Diabetes Care"},{"key":"208_CR53","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/dom.12262","volume":"16","author":"C Mathieu","year":"2014","unstructured":"Mathieu C, Rodbard HW, Cariou B, BEGIN: VICTOZA ADD-ON (NN1250-3948) study group, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16:636\u201344.","journal-title":"Diabetes Obes Metab."},{"key":"208_CR54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/dom.12225","volume":"16","author":"MC Riddle","year":"2014","unstructured":"Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab. 2014;16:396\u2013402.","journal-title":"Diabetes Obes Metab"},{"key":"208_CR55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885\u201393.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"208_CR56","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","volume":"37","author":"J Buse","year":"2014","unstructured":"Buse J, Vilsb\u00f8ll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926\u201333.","journal-title":"Diabetes Care"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0208-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T11:20:40Z","timestamp":1498216840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0208-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0208-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}